Support teaching, research, and patient care.
International
true
false
Hepatobiliary imagingHepatocellular carcinomaUrologic imagingGynecologic imagingThyroid imagingNovel ultrasound technologiesPerfusion CT imaging of abdominal tumors
BR55 in Characterization of Ovarian Lesions Not Recruiting
This is an exploratory phase II, single center, open label, prospective study of BR55 CEUS for characterization of ovarian lesions in subjects with suspected ovarian cancer.
Stanford is currently not accepting patients for this trial. For more information, please contact Aya Kamaya, 650-723-8463.
View full details
Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma Not Recruiting
To determine the efficacy and toxicity of TACE combined with SBRT
Stanford is currently not accepting patients for this trial. For more information, please contact Laurie Ann Columbo, 650-736-0792.
Development of 3D Multi-Parametric Ultrasound (MPUS) as a Decision Support Tool for Patients Recruiting
This clinical trial studies how well 3-dimensional multi-parametric ultrasound (3D MPUS) imaging works as a decision-support tool for patients with liver tumors undergoing therapy. Continuous and dynamic imaging of patients undergoing therapy is required to monitor early-phase treatment response. 3D-MPUS is an inexpensive and safe method, which may provide complementary quantitative functional (perfusion) and tissue characterization information to anatomical radiological assessment or blood biomarkers.
Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions Not Recruiting
This is an exploratory, single center, open label, parallel-dose, and prospective study of BR55 contrast-enhanced ultrasonography (CEUS) for characterization of solid pancreatic lesions in subjects with suspected pancreatic ductal adenocarcinoma (PDAC) using transabdominal US.
Stanford is currently not accepting patients for this trial. For more information, please contact Krithika Rupnarayan, MPH, MBBS, 650-736-0959.
Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC) Not Recruiting
To assess whether changes in quantitative tumor perfusion parameters after 3 weeks of treatment, as measured by power Doppler ultrasound, can predict initial objective response, defined by current standard-of-care, to therapy at 12 weeks after start of treatment
Stanford is currently not accepting patients for this trial. For more information, please contact Christian Hoerner, PhD, 650-721-3206.
Contrast-Enhanced Ultrasound Imaging in Diagnosing Liver Cancer in Patients With Cirrhosis Not Recruiting
This clinical trial studies how well contrast-enhanced ultrasound imaging works in diagnosing liver cancer in patients with cirrhosis. Diagnostic procedures, such as contrast-enhanced ultrasound imaging, may help find and diagnose liver cancer.
Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Pilot 3D Contrast-Enhanced Ultrasound Imaging to Predict Treatment Response in Liver Metastases Not Recruiting
Patients are invited to participate in a research study of liver perfusion (how blood flows to the liver over time). Researchers hope to learn whether perfusion characteristics of liver metastases may be predictive of response to treatment and whether liver perfusion characteristics can be used to follow response to treatment. Patients were selected as a possible participant in this study because they are identified as having liver metastases
Stanford is currently not accepting patients for this trial. For more information, please contact Risa Jiron, 650-736-1598.
Ultrasound Elastography in Imaging Patients With Thyroid Nodules Not Recruiting
This clinical trial studies how well ultrasound elastography works in assessing the cancer status of potentially malignant thyroid nodules.
Stanford is currently not accepting patients for this trial. For more information, please contact Harris Naemi, 650-736-6524.
B-mode Ultrasound Imaging in Detecting Early Liver Cancer Not Recruiting
This pilot trial studies how well B-mode ultrasound imaging works in detecting liver cancer that is early in its growth and may not have spread to other parts of the body. Diagnostic procedures, such as B-mode ultrasound imaging, may help find and diagnose liver cancer and find out how far the disease has spread.
Stanford is currently not accepting patients for this trial. For more information, please contact Sunitha Bachawal, 650-724-1472.
Ultrasound Elastography in Diagnosing Patients With Kidney or Liver Solid Focal Lesions Not Recruiting
This clinical trial studies ultrasound elastography in diagnosing patients with kidney or liver solid focal lesions. New diagnostic procedures, such as ultrasound elastography, may be a less invasive way to check for kidney or liver solid focal lesions.
Stanford is currently not accepting patients for this trial. For more information, please contact Juergen Willmann, 650-725-1812.
Phase I Pilot Study to Evaluate the Prognostic Value of Perfusion CT for Primary Cervical Cancer Not Recruiting
The investigators hope to learn whether perfusion CT is a useful way to assess primary cervical tumor microenvironment and whether there is a relationship between pretreatment perfusion CT measurements and primary cervical tumor size, lymph node involvement (as assessed by standard of care pretreatment fludeoxyglucose Positron emission tomography/CT (FDG-PET/CT)), and treatment response (as assessed by standard of care 3-month post-therapy FDG-PET/CT).
Stanford is currently not accepting patients for this trial. For more information, please contact Melissa Usoz, 650-723-8843.
Perfusion CT Monitoring to Predict Treatment Efficacy in Renal Cell Carcinoma Not Recruiting
This pilot clinical trial studies perfusion computed tomography (CT) in predicting response to treatment in patients with advanced kidney cancer. Comparing results of diagnostic procedures done before, during, and after targeted therapy may help doctors predict a patient's response to treatment and help plan the best treatment.
Stanford is currently not accepting patients for this trial. For more information, please contact Yoriko Imae, 650-498-5186.
Feasibility 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation Not Recruiting
The purpose of this study is to prospectively analyze the value of 3D ultrasound perfusion imaging for treatment planning, the prediction of therapy success, and to monitor the treatment response in patients with a primary or metastatic liver tumor undergoing radiation treatment.
Stanford is currently not accepting patients for this trial. For more information, please contact Jen-Yeu Wang, 650-723-3110.
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib Not Recruiting
This study is to determine whether JX-594 (Pexa-Vec) plus best supportive care is more effective in improving survival than best supportive care in patients with advanced Hepatocellular Carcinoma (HCC) who have failed sorafenib.
Stanford is currently not accepting patients for this trial. For more information, please contact Fizaa Ahmed, 6507256409.
